BioNTech Settles Vaccine Royalty Disputes

This is a news story, published by Yahoo Finance, that relates primarily to the U.S. National Institutes of Health news.

News about vaccine development

For more vaccine development news, you can click here:

more vaccine development news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about

certain patents

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest BioNTech news, lawsuit news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

vaccine maker

Reuters

•

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

Summary

Nutrition label

82% Informative

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine.

The German company partners with Pfizer for its vaccine, said it would pay $791.5 million to the agency under the agreement.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech